In this issue of THE JOURNAL, the Aptiganel Hydrochloride Acute Stroke
Investigators1 present the results of yet another
failed trial of neuroprotection for acute ischemic stroke. The continued negative
results of such trials are disappointing, but studies such as this one also
raise concerns. Compared with those who received placebo, patients who received
aptiganel hydrochloride within 6 hours of stroke onset tended to experience
increased morbidity and mortality. The independent data and safety monitoring
board suspended the trial after the interim (phase 2) analyses of 300 patients
were completed, but during the time needed for those analyses, 328 more patients
were enrolled in the trial and exposed to the risks of the experimental drug.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.